| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10964553 | Vaccine | 2014 | 11 Pages |
Abstract
An infant MenB vaccination program significantly exceeds commonly used cost-effectiveness thresholds and thus is unlikely to be considered economically attractive in Ontario and comparable jurisdictions.
Keywords
AEFIOHIPmenBSerogroup Bcase fatality ratioOCCIhSBAOntario Health Insurance ProgramMOHLTCICERQALYIMDQOLMATSmeningococcal antigen typing systemCCCCFRQuality of lifeInvasive meningococcal diseaseCommunicable diseasesCost and cost analysisAdverse Events Following ImmunizationImpactEconomicsNeisseria meningitidisIncremental cost-effectiveness ratioVaccinesComplex chronic conditionUnited KingdomTechnical assistancequality adjusted life year
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hong Anh T. Tu, Shelley L. Deeks, Shaun K. Morris, Lisa Strifler, Natasha Crowcroft, Frances B. Jamieson, Jeffrey C. Kwong, Peter C. Coyte, Murray Krahn, Beate Sander,